[WIRB] A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma

UCI-16-92
NCT02908672
Cancer - Melanoma, skin
John P Fruehauf
Open
Treatment
Atezolizumab, Cobimetinib, MPDL3280A, Placebo, Vemurafenib
III
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.